Joseph P. Eder

Yale University — United States

Medicine · Health Sciences

55h-index24.4kcitations330works3.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(73), Cancer therapeutics and mechanisms(66), Cancer Immunotherapy and Biomarkers(58), Lung Cancer Research Studies(44), Cancer Treatment and Pharmacology(41)

Publications330 total

AB010. A phase 1 trial of PRTH-101, a monoclonal antibody targeting discoidin domain receptor 1 (DDR1), alone or in combination with pembrolizumab, for the treatment of thymic malignancies
Mediastinum·2025· 1 citedOpen Access
AB013. A pivotal phase 2 trial to compare PRTH-101, a monoclonal antibody targeting discoidin domain receptor 1 (DDR1), in combination with an immune checkpoint inhibitor (ICI) and ICI alone, for the treatment of recurrent or metastatic thymic epithelial carcinoma (TEC)
Mediastinum·2025Open Access
Polymerase Ѳ inhibitors combinations with approved and investigational agents in patient-derived tumor multi-cell type (mct) spheroids
Experimental and Molecular Pathology·2025· 2 citedOpen Access
Polymerase Ѳ Inhibitors Combinations with Approved and Investigational Agents in Patient-Derived Tumor Multi-Cell Type (Mct) Spheroids
SSRN Electronic Journal·2025Open Access
Financial Toxicity Among Patients With Advanced Solid Tumors Participating in Early-Phase Clinical Trials
JCO Oncology Practice·2024· 1 citedOpen Access
Entwicklung von Standards für gesundheitsfördernde und klimafreundliche Gesundheitseinrichtungen
Das Gesundheitswesen·2024
Guidance on health promoting and climate-friendly hospitals and health services
European Journal of Public Health·2024Open Access
Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort
UNC Libraries·2024Open Access
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trials
Nature Communications·2024· 38 citedOpen Access
Abstract LB215: Polymerase θ (POLθ) inhibitors (novobiocin, ART-558, RP6685) were tested with 22 approved and investigational agents in multi-cell type spheroids of genetically selected patient-derived human tumor cell lines
Cancer Research·2024
Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors
JCO Precision Oncology·2024· 1 citedOpen Access
1486 DDR1 expression is associated with a worse prognosis in intrahepatic cholangiocarcinoma
Regular and Young Investigator Award Abstracts·2023Open Access
1079TiP A phase I first-in-human study of PRTH-101, an IgG1 monoclonal antibody targeting DDR1, as a monotherapy and combined with pembrolizumab in patients with advanced solid malignancies
Annals of Oncology·2023· 3 citedOpen Access
Platinum Sensitivity in<i>IDH1/2</i>Mutated Intrahepatic Cholangiocarcinoma: Not All “BRCAness” Is Created Equal
Cancer Investigation·2023· 1 cited
TABLE 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
2023Open Access
Data from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Table 2 from NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
2023Open Access
page 1 of 17Next →

Frequent Co-authors

Kenneth Emancipator(8), Karen H. Antman(7), Anthony Elias(7), Marisa Dolled‐Filhart(6), Barbara Burtness(6), Jonathan D. Cheng(6), Kei Muro(6), Shilpa Gupta(6), Kumudu Pathiraja(6), Geoffrey I. Shapiro(6), Edward B. Garon(5), Rina Hui(5), Natasha B. Leighl(5), Ani Sarkis Balmanoukian(5), Amita Patnaik(5), Jared Lunceford(5), Gregory M. Lubiniecki(5), Tanguy Y. Seiwert(5), Jared Weiss(5), Laura Q.M. Chow(5)